Sulindac reverses aberrant expression and localization of β-catenin in papillary thyroid cancer cells with the BRAFV600E mutation

Thyroid

Volumn 20, Issue 6, 2010, Pages 615-622

  Cho, Nancy L ^a   Lin, Chi Iou ^a   Whang, Edward E ^a   Carothers, Adelaide M ^a   Moore, Francis D ^a   Ruan, Daniel T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; CYCLIN D1; MYC PROTEIN; SULINDAC; BRAF PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTO ONCOGENE; RAT; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; THYROID GLAND; THYROID TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, PAPILLARY; ANIMALS; BETA CATENIN; CELL LINE, TUMOR; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RATS; SULINDAC; THYROID GLAND; THYROID NEOPLASMS;

EID: 77953918459     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0415     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer statistics. CA Cancer J Clin 58:71-96.
2. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G 2002 Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963:116-121.
3. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63: 4561-4567.
4. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET=PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457.
5. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627.
6. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M 2003 BRAF mutations and RET=PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580.
7. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23:7436-7440.
8. Abbosh PH, Nephew KP 2005 Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid 15: 551-561.
9. Reya T, Clevers H 2005 Wnt signalling in stem cells and cancer. Nature 434:843-850. (Pubitemid 40558990)
10. Tetsu O, McCormick F 1999 Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW 1998 Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512.
12. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y 2002 Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin=Tcf4 complex in human colorectal cancers. Oncogene 21:5861-5867.
13. Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, Hayashi T, Maeda S, Ichinose M, Kanematsu T, Yamashita S 2002 Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433-3440.
14. Weinberger PM, Adam B-L, Gourin CG, Moretz WH, Bollag RJ, Wang BY, Liu Z, Lee JR, Terris DJ 2007 Association of nuclear, cytoplasmic expression of galectin-3 with b-catenin= Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 33:503-510.
15. Rezk S, Brynes RK, Nelson V, Thein M, Patwardhan N, Fischer A, Khan A 2004 Beta-catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol 15:329-337.
16. Nakashima M, Meirmanov S, Naruke Y, Kondo H, Saenko V, Rogounovitch T, Shimizu-Yoshida Y, Takamura N, Namba H, Ito M, Abrosimov A, Lushnikov E, Roumiantsev P, Tsyb A, Yamashita S, Sekine I 2004 Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant b-catenin expression. J Pathol 202:446-455.
17. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B 2006 Derangement of the E-cadherin=catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 191:581-587.
18. Mahmoud NN, Boolbol SK, Bilinski RT, Martucci C, Chadburn A, Bertagnolli MM 1997 Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res 57:5045-5050.
19. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli MM 1998 Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 124:225-231.
20. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ 2003 Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2:885-892.
21. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU 2003 A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899.
22. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B 2006 Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895. (Pubitemid 44315981)
23. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB,Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B 2000 The effect of celecoxib, a cyclooxygenase- 2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952.
24. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET 2006 Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884. (Pubitemid 44315980)
25. Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, Fusco A, Fagin JA 2003 Conditional expression of RET=PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol 17:1425-1436.
26. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr., Zhang L, Fagin JA 2005 Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65: 2465-2473.
27. Ahmad M, Shi Y 2000 TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene 19:3363-3371.
28. Rao AS, Kremenevskaja N, von Wasielewski R, Jakubcakova V, Kant S, Resch J, Brabant G 2006 Wnt=beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. J Clin Endocrinol Metab 91:159-168.
29. De Nigris F, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G, Santelli G, Fusco A 2002 Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer 86:917-923.
30. Lin CI, Whang EE, Abramson MA, Donner DB, Bertagnolli MM, Moore FD Jr., Ruan DT 2009 Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 379:626-631.
31. Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Dunach M, Elliott BE, Hoppener JW, Mulligan LM 2008 A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res 68:1338-1346.
32. Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F, Fusco A, Gutkind JS, Santoro M 2009 The betacatenin axis integrates multiple signals downstream from RET=papillary thyroid carcinoma leading to cell proliferation. Cancer Res 69:1867-1876.
33. Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG, Lanzi C 2009 RET=PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and b-catenin nuclear translocation. Neoplasia 11:10-21.
34. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C, Bondanelli M, degli Uberti EC 2005 Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 90:5754-5760.
35. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65:4238-4245.
36. Mesa C Jr., Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA 2006 Conditional activation of RET=PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66:6521-6529.
37. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-470; discussion 470-471.
38. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397.
39. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404.
40. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS 2005 Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310:1504-1510.
41. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH 2006 Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91:2201-2204.